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Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by degeneration of
alpha motor neurons in the spinal cord, resulting in progressive proximal muscle weakness and paralysis. Estimated
incidence is 1 in 6,000 to 1 in 10,000 live births and carrier frequency of 1/40-1/60. This disease is characterized by
generalized muscle weakness and atrophy predominating in proximal limb muscles, and phenotype is classified
into four grades of severity (SMA I, SMAII, SMAIII, SMA IV) based on age of onset and motor function achieved. This
disease is caused by homozygous mutations of the survival motor neuron 1 (SMN1) gene, and the diagnostic test
demonstrates in most patients the homozygous deletion of the SMN1 gene, generally showing the absence of
SMN1 exon 7. The test achieves up to 95% sensitivity and nearly 100% specificity. Differential diagnosis should be
considered with other neuromuscular disorders which are not associated with increased CK manifesting as infantile
hypotonia or as limb girdle weakness starting later in life.
Considering the high carrier frequency, carrier testing is requested by siblings of patients or of parents of SMA
children and are aimed at gaining information that may help with reproductive planning. Individuals at risk should
be tested first and, in case of testing positive, the partner should be then analyzed. It is recommended that in case
of a request on carrier testing on siblings of an affected SMA infant, a detailed neurological examination should be
done and consideration given doing the direct test to exclude SMA. Prenatal diagnosis should be offered to
couples who have previously had a child affected with SMA (recurrence risk 25%). The role of follow-up
coordination has to be managed by an expert in neuromuscular disorders and in SMA who is able to plan a
multidisciplinary intervention that includes pulmonary, gastroenterology/nutrition, and orthopedic care. Prognosis
depends on the phenotypic severity going from high mortality within the first year for SMA type 1 to no mortality
for the chronic and later onset forms.
Keywords: Proximal spinal muscular atrophy, SMN1, SMN2, motor neurons Disease names and synonyms: Spinal
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Definition
Spinal muscular atrophy (SMA) is a severe neuromuscu-
lar disease characterized by degeneration of alpha motor
neurons in the spinal cord, resulting in progressive
proximal muscle weakness and paralysis. The disease
was first described in the 1890s by Werdnig [1] and by
Hoffmann [2]. The genetic defect was localized to
5q11.2-q13.3 a century later [3] with the identification
of the survival motor neuron gene (SMN) gene as the
disease-causing gene in 1995 [4].
Epidemiology
SMA is the second most common fatal autosomal reces-
sive disorder after cystic fibrosis, with an estimated inci-
dence of 1 in 6,000 to 1 in 10,000 live births, with a
carrier frequency of 1/40-1/60 [5,6].
Clinical description and Classification
SMA is clinical classified into four phenotypes on the
basis of age of onset and motor function achieved [7]
(See table 1).
SMA type 1 (Werdnig-Hoffmann disease) is the most
severe and common type, which accounts for about 50%
of patients diagnosed with SMA. Classically infants with
SMA type I have onset of clinical signs before 6 months
of age, never acquire the ability to sit unsupported and,
if no intervention is provided, generally do not survive
beyond the first 2 years. Thesep a t i e n t sh a v ep r o f o u n d
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head control. Spontaneous motility is generally poor and
antigravity movements of limbs are not typically
observed. In the most severe forms decreased intrauter-
ine movements suggest prenatal onset of the disease and
present with severe weakness and joint contractures at
birth and has been labeled SMN 0. Some of these chil-
dren may show also congenital bone fractures and extre-
mely thin ribs [8-11].
Within SMA type I at least 3 clinical subgroups can
be defined according to the severity of clinical signs: a)
severe weakness since birth/neonatal period, head con-
trol is never achieved; b) onset of weakness after the
neonatal period but generally within 2 months, head
control is never achieved; c) onset of weakness after the
neonatal period but head control is achieved. Some of
these children may be able to sit with support [12].
Clinically, all children with SMA type I show a combi-
nation of severe hypotonia and weakness, with sparing
of the facial muscles, invariably associated with a typical
respiratory pattern. The weakness is usually symmetrical
and more proximal than distal, with lower limbs gener-
ally weaker than upper limbs. Deep tendon reflexes are
absent or diminished but sensitivity is preserved.
The spared diaphragm, combined with weakened
intercostal muscles, results in paradoxical breathing.
The involvement of bulbar motorneurons often give
tongue fasciculation, poor suck and swallow with
increasing swallowing and feeding difficulty over time.
Aspiration pneumonia is an important cause of morbid-
ity and mortality.
In the last few years there has been increasing evi-
dence that some cases with severe SMA type I (generally
carrying 1 copy of SMN2) may have heart defects
[13,14], mostly atrial and ventricular septal defects and a
possible involvement of the autonomic system that may
be responsible for arrhythmia and sudden death.
SMA type II is characterized by onset between 7 and
18 months of age. Patients achieve the ability to sit
unsupported and some of them are able to acquire
standing position, but they do not acquire the ability to
walk independently. Deep tendon reflexes are absent
and fine tremors of upper extremities are common.
Joint contractures and kyphoscoliosis are very common
and can occur in the first years of life in the more
severe type II patients. Weak swallowing can be present
but is not common [15] while weakness of the mastica-
tory muscles more often affect the ability to chew.
There is a spectrum of severity ranging from weak chil-
dren who are just able to sit unsupported and are more
prone to respiratory signs and early scoliosis to relatively
stronger children who have much stronger trunk, limb
and respiratory muscles. Patients at the weak end of the
spectrum may develop respiratory failure requiring
mechanical ventilation.
SMA type III (Kugelberg-Welander disease) includes
clinically heterogeneous patients. They typically reach all
major motor milestones, as well as independent walking.
However during infancy they develop proximal muscular
weakness. Some might need wheelchair assistance in
childhood, whereas others might continue to walk and
live productive adult lives with minor muscular weak-
ness. Patients who lose ambulation often develop scolio-
sis and other medical problems related to poor mobility
such obesity and osteoporosis [16-18]. Concerning nat-
ural history data on 329 SMA type III patients, 2 sub-
groups of severity have been suggested on the
probability of being able tow a l kb y1 0y e a r sa n do n
increased probability to lose walking by the age of 40
years. Significant differences loosing ability to walk were
observed in relation to those with an onset of weakness
before (SMA III a) and after age 3 years of age (SMA
IIIb) [19].
SMA type IV has been added to this classification to
describe those patients with adult onset (> 18 ys) and
mild course. This group includes patients who are able
to walk in adulthood and without respiratory and nutri-
tional problems.
Since all SMA types belong to a single spectrum and
share the same etiology, patient selection for clinical
trials is actually independent of the historical classifica-
tion, and is essentially determined by the intervention
characteristics and the choice of endpoints.
Molecular genetics and Etiology
Two almost identical SMN genes are present on chro-
mosome 5q13: the telomeric or SMN1 gene, which is
the spinal muscular atrophy- determining gene, and the
centromeric or SMN2 gene.
The coding sequence of SMN2 differs from that of
SMN1 by a single nucleotide (840C > T), which does
not alter the aminoacidic sequence but results in
Table 1 Clinical classification criteria for spinal muscular atrophy
Age of onset Highest function achieved
Type I (Werdnig-Hoffmann disease) 0-6 months Never sit
Type II (intermediate) 7-18 months Sit never stand
Type III (mild, Kugelberg-Welander disease) in adulthood > 18 months Stand and Walk during aldulthood
Type IV (adult) 2°-3° decade Walk unaided
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splicing of exon 7, SMN2 g e n e sp r o d u c ear e d u c e d
amount of full length transcripts (SMN-fl) and protein,
and a variable amount of mRNA lacking exon 7 (10% to
50%, SMN-del7) which give raise to a truncated and
unstable protein [20]. About 95% of patients have a
homozygous disruption of SMN1 due to deletion or
gene conversion of SMN1 to SMN2 [21]. About 3% of
affected individuals are compound heterozygotes for
deletion of one SMN1 allele and subtle intragenic muta-
tions. All patients, however, retain at least one copy of
SMN2, generally 2-4. Loss of SMN1 is essential to the
pathogenesis of SMA, while the severity of the disease is
primarily related to the number of copies of SMN2.
Most SMA type I patients have two copies of SMN2
[22], three SMN2 copies are common in SMA type II,
while type III and IV generally have three or four
[23,24].
SMN g e n e se n c o d ef o rS M Np r o t e i nw h i c hi su b i q u i -
tously expressed and localized in the cytoplasm and in
the nucleus, and is particularly abundant in motor neu-
rons of the spinal cord [25]. Within the nucleus, SMN
protein is concentrated in dot-like structures associated
with coiled (Cajal) bodies, named “gems” (gemini of
coiled bodies) [26]. Although the exact cellular function
of SMN protein responsible for the pathogenesis of
SMA remains unknown, cells from patients with spinal
muscular atrophy contain fewer gems compared con-
trols and carriers [26].
Animal models by disruption of SMN has been
obtained in yeast, nematode,f l y ,z e b r a f i s h ,a n dm o u s e .
These models of spinal muscular atrophy have not
only been fundamental for increasing knowledge
about the molecular and cellular pathways of SMN,
but also to better understand the mechanism(s) of dis-
ease, and to provide a platform from which high-
throughput genetic and drug screens can be per-
formed [27]. However Spinal muscular atrophy mutant
mice that die soon after birth (low copy SMN2+/+;
Smn -/-) preclude detailed analysis of pathogenic
mechanisms and preclinical drug testing [28] How-
ever, this disease severity can be tempered to inter-
mediate and mild phenotypes by adding additional
transgenes that express various wild-type isoforms or
weak mutant forms of SMN [29].
Two main hypothesis have been postulated to explain
t h ep a t h o g e n e s i so fS M A :( a )S M Ni si n v o l v e di nt h e
biogenesis of small nuclear ribonucleoproteins (snRNPs)
and in mRNA splicing: thus SMN reduction may deter-
mine a general perturbation in snRNP assembly (to
which motor neurons may be more sensitive), and/or
SMN complex is involved in the splicing of one or few
transcripts with a key function in motor neurons; or (b)
SMN has a motor neuron specific function, independent
from snRNPs assembly, such as mRNA transport along
the axon.
Hypothesis (a) is supported by different experimental
evidences: SMN protein is a part of a high molecular
weight complex including at least eight other proteins,
and it is necessary for proper assembly of Smith class
core proteins in the Uridine-rich snRNPs (U snRNP). U
snRNPs are the principal components of spliceosomes,
the cellular particles that executes pre-mRNA splicing.
Although SMN protein is expressed in all somatic cells,
why motor neurons of the spinal cord are specifically
vulnerable in spinal muscular atrophy is puzzling. Some
studies suggest that SMN protein might play a key role
in cellular functions unique to motor neurons [30-32].
Also hypothesis (b) is supported by different lines of
evidence: several studies suggest that SMN protein
might sustain the survival of motor neurons by allowing
normal axonal transport and maintaining the integrity
of neuromuscular junctions. Low concentrations of
SMN protein might be specifically detrimental to motor
neurons due to the length of axons and to their unique
interactions with skeletal muscles [33-40]. Furthermore,
SMN protein is localized in ribonucleoprotein granules
in neurites and growth cones of motor neurons; for this
reason some Authors suggested that SMN protein might
be involved in transportation of ribonucleoprotein com-
plexes containing b-actin, and/or specific mRNAs [41].
Very recently, in a mouse model of SMA it has been
observed that morphological changes occurring at early
stages of the disease, include reduced proprioceptive
reflexes that correlate with decreased number and func-
tion of synapses on motor neuron somata and proximal
dendrites. These changes occur first in motor neurons
innervating proximal hindlimb muscles and in medial
motor neurons innervating axial muscles. At an end-
stage disease deafferentation of motor neurons occur for
motor neurons innervating distal hind limb muscles.
Motor neuron loss follows afferent synapse loss with the
same temporal and topographical pattern [42].
Diagnosis
Clinical features are highly suggestive for the diagnosis
of SMA particularly in the severe variant of a floppy
baby or weak child. The attentiveness and intellect is
always good. The weakness is usually symmetrical and
more proximal than distal; generally it is greater in the
legs than in the arms. The severity of weakness corre-
lates with the age of onset with delayed motor mile-
stones according to clinical classification (see table 1).
Sensitivity is preserved and deep tendon reflexes are
more or less involved depending on age at onset and
duration of the disease. In the most severe form more-
over other clinical features include: impaired head con-
trol, weak cry and cough, swallowing and feeding
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Page 3 of 10difficulty, atrophy and fasciculation of the tongue and
the infant relies on the diaphragm for breathing
(abdominal breathing)..
T h ea l g o r i t h mo ft h ed i a g n o s t i cp r o c e d u r e st h a t
should be guide to diagnosis of SMA is summarized in
Figure 1.
The first level diagnostic test for a patient suspected
to have SMA should be the search of SMN1 gene
homozygous deletion. The absence of SMN1 exon 7
(with or without deletion of exon 8) confirms the diag-
nosis of SMA. The test achieves up to 95% sensitivity
and nearly 100% specificity [43].
If the first level assay tests negative, further laboratory
exams including creatine kinases dosage and electrophy-
siological tests such as electromyography (EMG), and
nerve conduction study should be performed. If EMG
suggests a motor neuron disease, then further testing for
SMN mutations should be pursued. Genetic tests now
offer quick and reliable SMN1 gene copy number testing
by using Multiplex ligation-dependent probe
amplification (MLPA) or real time PCR. Semiquantita-
tive assays improve diagnostic sensitivity up to 98%
[24,44]. If the patient has a single SMN1 copy, it is man-
datory to sequence the coding region of the undeleted
allele to identify the second causative mutation, gener-
ally subtle sequence variations, including point muta-
tions, insertions, and deletions. However, in about one
third of patients with a typical clinical picture and a sin-
g l eS M N 1c o p y ,t h es e c o n dm u t a t i o ni sn o tf o u n di n
SMN1/SMN2 coding region. This finding is more com-
mon in type III SMA and might be due to the presence
of deep intronic mutations, unidentified so far (personal
unpublished observation). Finally, sequence analysis of
SMN1 gene is suggested also in those patients who have
a typical clinical picture, 2 SMN1 copies, and are born
to consanguineous parents or originate from genetic iso-
lates. Indeed, rare patients homozygous for SMN1 subtle
mutations have been occasionally reported [45].
Conversely, in a patient with 2 SMN1copies, SMA
diagnosis, related to SMN1 mutations is virtually
Figure 1 Diagnostic algorithm for spinal muscular atrophy.
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spinal muscular atrophy with respiratory distress
(SMARD1), X-linked spinal muscular atrophy, distal
SMA, and juvenile amyotrophic lateral sclerosis should
be considered.
If the electrophysiological examination excludes a
motor neuron disease the child should be reexamined
and must receive additional diagnostic testing consider-
ing other disorders.
Differential diagnosis
In general, the most important differential diagnostic
conditions for an infant presenting with hypotonia and/
or weakness are congenital myopathies, i.e. myopathies
with typical structural or ultrastructural features (rods,
cores, central nuclei) on the muscle biopsy, congenital
myotonic dystrophy, congenital myasthenic syndromes,
metabolic myopathies, congenital disorders of the motor
neuron and the peripheral nerve (congenital hypomyeli-
nating neuropathy), as well as non-neuromuscular con-
ditions including genetic syndromes such as, Prader-
Willi syndrome, acute hypoxic ischemic encephalopathy,
neonatal sepsis and dyskinetic or metabolic conditions.
The most important tools to address these differential
diagnostic possibilities beyond the clinical examination
and a careful family history are CK determination (note
however that the CK can be only moderately elevated in
chronic forms of SMA), EMG/nerve conduction studies
to discriminate neurogenic conditions and abnormalities
of neuromuscular transmission, MRI of the brain, mus-
cle biopsy, and specific genetic or metabolic testing,.
Other inherited motor neuron disorders, not caused
by mutation of the SMN gene, that present with early
weakness should be considered and are listed in table 2.
Some clinical symptoms may suggest the diagnosis
including joint contractures, distal rather than proximal
weakness, diaphragmatic paralysis with early respiratory
failure, and pontocerebellar degeneration.
Genetic counseling and prenatal diagnosis
Spinal muscular atrophy is one of the most common
genetic disorders, with a carrier frequency of about 1/
50, and direct carrier testing could be beneficial to com-
munity as screening test. Since the most common muta-
tion found in patients is the homozygous absence of
SMN1 gene, the majority of carriers bear the heterozy-
gous deletion of one SMN1 allele. As in the case of sec-
ond level diagnostic test, carrier testing is based on
semiquantitative real time PCR or MLPA. Since the sen-
sitivity of the molecular test is 93-95% [43], it is impor-
tant to provide all couples performing molecular test
with formal genetic counselling for the assessment of
residual risk of having a child affected from SMA. The
carrier test does not always identify if SMA is present
and is not typically performed until the sibling is of
childbearing age.
Thus it is imperative that individuals understand the
limitations of the molecular testing: subjects who test
negative for the search of heterozygous deletion may
have two SMN1 copies in cis on one chromosome 5,
may be carriers of rare subtle mutations, and the occur-
rence of extremely rare de-novo mutations cannot be
r u l e do u t .A s( i nt h ec a s eo fo t h e r )i st r u ef o rc a r r i e r
screening programs, SMA testing must be voluntary,
performed in adults only, and upon informed consent
and assurance of confidentiality [6].
In most cases, carrier testing is requested by siblings
of patients or of parents of SMA children and are aimed
at gaining information that may help with reproductive
planning (prenatal diagnosis or pre-implantation diagno-
sis). In these cases, we suggest to test at risk individuals
first and, in case of testing positive, to analyze also the
partner. Thus in case of a request on carrier testing on
siblings of an affected SMA infant, a detailed neurologi-
cal examination should be done and consideration given
doing the direct test to exclude SMA.
Prenatal diagnosis should be offered to couples who
have previously had a child affected with SMA (recur-
rence risk 25%); in these cases, antenatal screening by
chorionic villi sampling can be carried out between the
11
th and 13
th week of pregnancy. In all other instances,
i.e. relatives of patients, carrier testing is sufficient to
reduce markedly the risk of SMA for the offspring. In
our opinion, prenatal diagnosis should be offered only
Table 2 other forms of SMA not linked to SMN gene
SMA variant Inheritance/gene Clinical features
Scapuloperoneal SMA AD
12q24.1-q24.31
Progressive weakness of scapuloperoneal and laryngeal muscles
SMA with pontocerebellar hypoplasia AR VRK1 Brainstem and cerebellar hypoplasia, early onset (0-6 mo)
X-linked infantile SMA with
arthogryposis
X-linked Xp11.3-q11.2
UBA1
Contractures, onset at birth or infancy, early death
SMA with respiratory distress type I AR-IGHMBP2 Early onset (< 3 mo), eventration of diaphragms, distal weakness, pes
equines.
Congenital distal SMA AD12q23-q24 Early onset with contractures, nonprogressive
Distal SMA-V/CMT2d AD 7p15 GARS Distal SMA with upper limb predominance
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however, the clinical severity of a potentially affected foe-
tus cannot be established a priori and the predictive
power of SMN2 copy number assessment is not sufficient
to establish an accurate prognosis. Indeed testing for
SMN2 copy number in an affected fetus is problematic
when there are 3 copies, as types I, II and III can all result
in this setting and thus no prognosis can be established.
H a v i n gas i n g l ec o p yi sr a r eb u ti sh i g h l yp r e d i c t i v eo fa
severe type I baby with a very poor prognosis. A copy
number of 2 is typical for a type I phenotype but could
be a type II, again making any prognosis difficult. These
considerations and facts have impact on neonatal screen-
ing, an argument that is growing with the progress in
treatment prospective in SMA [6]. The purpose of new-
born screening is to identify affected infants prior to the
presentation of clinical symptoms. Newborn screening
has been an extremely successful program and has
improved the quality of life of many children with a vari-
ety of disorders. There has now been an expansion of the
number of conditions included in many newborn screen-
ing panels. The benefits achieved through newborn
screening have traditionally referred to the direct benefits
to the affected child. However, there are currently a num-
ber of disorders screened which do not have a well-
defined medical treatment, and this is the case for SMA.
While a number of potential therapies are currently in
clinical trials for SMA [46-50], their success may depend
on identifying individuals as early as possible in order to
begin treatment before potentially irreversible neuronal
loss. In infants with type I SMA, rapid loss of motor
units occurs in the first 3 months and severe denervation
with loss of more than 95% of units within 6 months of
age [51]. Therefore a very small window for beneficial
therapeutic intervention exists in infants with type I
SMA. Therapies would need to be administered within
the newborn period for maximum benefit which could
potentially be accomplished through a newborn screen-
ing program for SMA.
Management
A first consensus for standards of care of SMA has been
achieved in recent years [43]. Because of the complexity
of medical problems associated with the diagnosis of
SMA the primary care plays a central role in coordinat-
ing the follow-up and care. The role of follow-up coor-
dination has to be managed by an expert in
neuromuscular disorders and in SMA who is able to
plan a multidisciplinary intervention that includes pul-
monary, gastroenterology/nutrition, and orthopedic care.
Pulmonary disease is the major cause of morbidity and
mortality in SMA types I and II and may occur in a
small proportion of patients with type III. Respiratory
failure is caused by a greater involvement of expiratory
and intercostal muscles whereas the diaphragm is rela-
tively spared. Swallowing dysfunction and reflux are
important contributors to pulmonary morbidity. Patient
initially has recurrent chest infections, followed by noc-
turnal oxygen desaturation, nocturnal hypoventilation,
and then daytime hypercarbia [52-54].
Recommendations for respiratory assessment include
evaluation of cough effectiveness, observation of breath-
ing, and monitoring gas exchange. Respiratory muscle
function tests are indirect measures of cough effective-
ness and include peak cough flow, maximal inspiratory
pressure, and maximal expiratory pressure. In case of a
diagnosis of weak cough effectiveness cough-assist
device and oral suction pump is advised. Overnight
pulse oximetry with chart recording can be used to
screen for nocturnal hypoxemia. Polysomnography with
transcutaneous CO2 measurement are useful tools to
assess sleep-related hypoventilation.
When nocturnal hypoventilation is detected nocturnal
noninvasive ventilation (NIV) must be started with bi-
level positive pressure support. NIV can be used as a
routine therapy (also in daytime when it is needed) or
as a palliative tool. A key goal is to prevent pediatric
intensive care unit stays and avoid tracheotomy if possi-
ble. NIV should be the first choice to avoid
tracheostomy.
Additional therapies are medical or surgical gastroeso-
phageal reflux disease management and nutritional sup-
port orally or via a gastrostomy.
In SMA patients muscle weakness resulting in con-
tracture formation, spinal deformity, limited mobility
and activities of daily living, and increased risk of pain,
osteopenia, and fractures. Infants should have appro-
priate evaluation for their presenting musculoskeletal
and functional deficits. Goals of therapy and surgery
depend on functional level and the family’sw i s h e s .
Whenever possible, walking should be encouraged with
appropriate assistive devices and orthotics. Hip sub-
luxation is rarely painful, and there is a high risk of
recurrence despite surgical correction. Spinal orthoses
may provide postural support but do not prevent curve
progression and may impair respiratory effort. Scoliosis
surgery appears to benefit patients who survive beyond
2 years of age when curves are severe and progressive
and should be performed while pulmonary function is
adequate. Over the past few years newer surgical treat-
ments have been developed for the management of
severe scoliosis in skeletally immature patients prior to
definitive spinal fusion. Growing-rods [55] or Vertical
Expandable Prosthetic Titanium Rib (VEPTR) [56] may
be used to prevent the progression of the curve in very
young children when bracing isn’t successful.
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Actually no cure is available for SMA, and the patho-
genesis of the disorder is not completely understood. In
the last few years however many progresses in under-
standing the molecular basis of the disease has been
made and different therapeutic approaches are develop-
ing [57].
Pharmacological therapies
Several mechanisms have been targeted in SMA drug
trials such as neuroprotective drugs to rescue motor-
neurons (as riluzole), creatine to improve energy meta-
bolism, and albuterol for its anabolic properties and the
molecular effect on SMN2 gene expression [58]. Preli-
minary therapeutic efforts have been dominated by
drugs targeting to the modulation of SMN2 pre-mRNA
splicing, aimed at increasing SMN-fl levels, or to the
enhancement of SMN2 promoter activity. An alternative
therapeutic strategy is based on the use of antisense oli-
gonucleotides (ASOs) targeting the 3’ splice site (ss) of
exon 8 [59] and inhibiting the function of a negative
splicing regulator (E1) within intron 6. The antisense
strategy has further evolved by the development of alter-
native chemistries and through the incorporation of an
untethered binding platform for positively acting spli-
cing factors to the SMN2 exon 7 region. This has been
accomplished by combining the antisense region with
either a covalently bound synthetic peptide or with a
non-complementary ESE (exon splicing enhancer)
sequence acting as a binding platform for SR proteins
(bifunctional RNAs) [60]. Similar to the synthetic RNAs,
bifunctional RNAs may be expressed from AAV vectors,
leading to increased SMN protein levels in cell-based
models [61].
Following extensive high throughput screening of
SMN promoter-activating compounds, novel quinazoline
derivatives were recently developed, which not only
increased SMN in vitro, but also improved the SMA
phenotype in the SMNΔ7 mouse model [62,63].
An alternative strategy has been proposed by Mattis et
al. (2006) [64]: aminoglycosides induce the read-through
of the stop codon located in exon 8 of the SMN-del7
protein, thus elongating the C-terminus and stabilizing
the protein in vitro. Successful read-through has also
been achieved using different scaffolds with acceptable
safety profiles as shown by PTC Therapeutics in a clini-
cal trial with cystic fibrosis patients [65].
The group of compounds, histone deacetylase (HDAC)
inhibitors, has shown promise in several models of neu-
rodegeneration including SMA mouse models and
patients [66]. Positive results have been obtained in
murine SMA models with trichostatin A, sodium buty-
rate, and valproic acid [67-69]. Despite these pre-clinical
encouraging results, clinical trials have not given efficacy
outcomes using valproate and phenylbutyrate besides
good safety profiles [70]. New generation of HDAC inhi-
bitor compounds may hold promise since it has been
shown that LBH589 increased SMN levels in cells from
patients unresponsive to valproic acid [71], and SAHA
a d m i n i s t r a t i o ni n c r e a s e dl i f e s p a ni na nS M Am o u s e
model [72].
Gene therapy
In addition to possible drug therapy, gene therapy
approaches have been evaluated for SMA, using viral vec-
tors to replace SMN1 [73]. In a series of experiments, self-
complementary AAV8-hSMN was injected at birth
intrathecally into the CNS of SMA-like mice, increasing
the median life span of affected animals up to 50 days,
compared with 15 days for untreated controls [74]. In
another study, self-complementary adeno-associated virus
(scAAV9) vectors were intravenously injected at postnatal
day 1. Survival analysis showed that this treatment rescued
100% of treated animals, increasing life expectancy from 27
to over 340 days (median survival of 199 days). The sys-
temic scAAV9 therapy mediated complete correction of
motor function, prevented MN death and rescued the
weight loss phenotype close to normal [75]. Fourt et al
have shown that self-complementary adeno-associated
virus 9 (scAAV9) can infect approximately 60% of motor
neurons when injected intravenously into neonatal mice.
The scAAV9 was delivered at postnatal day 1 in SMA-like
pups and rescued motor function, neuromuscular physiol-
ogy and life span of affected mice. Later treatment (postna-
tal day 5) resulted in partial correction of the phenotype,
whereas postnatal day 10 treatment had little effect, sug-
gesting a developmental window during which scAAV9
therapy has maximal benefit. Notably the Authors reported
extensive scAAV9-mediated motor neuron transduction
after injection into a newborn cynomolgus macaque
demonstrating that scAAV9 crosses the blood-brain barrier
in a non-human primate and emphasizing the clinical
potential of scAAV9 gene therapy for SMA [76].
Adeno-associated virus (AAV) vectors have also been
used to deliver ASOs to the central nervous system by
intrathecal infusion. Passini et al (2011) have shown a
very efficient transfer rate of oligounucleotides, with
increased expression SMN-fl in mice models, and pro-
vided evidence that this route of administration has a
higher efficiency than systemic delivery [77].
Stem cell therapy
Stem cell approaches offer promise as a cellular replace-
ment strategy in the treatment of SMA and it is cur-
rently receiving considerable attention [78,79]. Cell
replacement may be achieved by transplantation of stem
D’Amico et al. Orphanet Journal of Rare Diseases 2011, 6:71
http://www.ojrd.com/content/6/1/71
Page 7 of 10cell-derived cells which have undergone maturation in
vitro, or by activation of endogenous stem cells in the
CNS. Bone marrow transplantation and mesenchimal
cells are the only stem cell therapy currently in use, but
no experience has been reported in SMA research. Sig-
nificant progress has been obtained using primary
neural stem cells derived from spinal cord, demonstrat-
ing improvement of the spinal muscular atrophy pheno-
type in mice, although this primary source has limited
translational applications [80]. In another study these
Authors used pluripotent stem cells derived from
embryonic stem cells showing the same potential thera-
peutic effects [81] by injecting ES cell-derived neural
cell precursors, into the spinal cord of a relatively severe
SMA mouse model. More recently the successful gen-
eration of induced pluripotent stem (iPS) cells from
patient fibroblast is an important step towards the gen-
eration of genetically compatible neurons for stem cell
therapy [82].
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